In the LIBRETTO-001 trial (phase 1/2, NCT03157128), 45 patients with RET fusion-positive solid tumors (excluding lung or thyroid tumors) were enrolled, including two patients with CCA. This evidence concerns the gene RET and cholangiocarcinoma.